title: Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets.
abstract: The effects of a single treatment or chronic administration of cabergoline (1-[(6-allylergolin-8beta-yl)carbonyl]-1-[3-(dimethylamino)p ropyl]-3-ethyl-urea), a potent, long-lasting dopamine receptor agonist, on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in common marmosets were studied. The administration of 0.2 mg/kg or a higer dose of cabergoline began to reverse parkinsonism-like symptoms 60 min after a subcutaneous injection, and showed steady and constant effects throughout the observation period. For prolonged administration, 0.2 mg/kg cabergoline was injected daily for 22 consecutive days. Locomotor activity in MPTP-treated animals increased until it reached its peak on the third day, then it gradually decreased. Akinesia scores, rating the quality of movements, were also improved, and the improvement was sustained up to the last day of chronic administration. None of the animals developed abnormal behaviors after either acute or chronic administration. These results suggest that cabergoline has long-acting effects in the marmoset model of parkinsonism, and that it will be a useful agent for the treatment of Parkinson's disease, particularly in cases with fluctuating motor disabilities.
authors.affiliation: Department of Pharmacology, Kagoshima University School of Medicine, Sakuragaoka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nomoto
authors.forename: S
authors.initials: S
authors.lastname: Kita
authors.forename: S I
authors.initials: SI
authors.lastname: Iwata
authors.forename: S
authors.initials: S
authors.lastname: Kaseda
authors.forename: T
authors.initials: T
authors.lastname: Fukuda
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D000077465:Cabergoline; D002144:Callithrix; D015259:Dopamine Agents; D018491:Dopamine Agonists / Q000494:pharmacology*; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology
chemical_list: D015259:Dopamine Agents; D018491:Dopamine Agonists; D004873:Ergolines; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000077465:Cabergoline